Kantarjian et al53 assessed the efficacy and protection of dasatinib, as compared with imatinib, for the initial-line cure of CML-CP. 5 hundred and nineteen patients with newly diagnosed CML-CP had been randomly assigned to acquire dasatinib in a dose of a hundred mg the moment every day (259 sufferers) or https://cicerol308ych0.wonderkingwiki.com/user